Enhanced expression of vascular cell adhesion molecule-1 by corticotrophin-releasing hormone contributes to progression of atherosclerosis in LDL receptor-deficient mice

Atherosclerosis

Volumn 203, Issue 2, 2009, Pages 360-370

  Wu, Yuqing ^a,b   Zhang, Rongjian ^a   Zhou, Chenghua ^b   Xu, Youhua ^a   Guan, Xiaowei ^a   Hu, Jue ^a   Xu, Yinyan ^a   Li, Shengnan ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

^b XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Atherosclerosis; Cell adhesion molecule; Corticotrophin releasing hormone; Inflammation; Transcription factor

Indexed keywords

5 CHLORO 4 [N (CYCLOPROPYLMETHYL) N PROPYLAMINO] 2 METHYL 6 (2,4,6 TRICHLOROANILINO)PYRIMIDINE; ANTISAUVAGINE 30; CORTICOTROPIN RELEASING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LOW DENSITY LIPOPROTEIN RECEPTOR; MESSENGER RNA; VASCULAR CELL ADHESION MOLECULE 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA ATHEROSCLEROSIS; ARTICLE; ATHEROGENESIS; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG INHIBITION; DRUG TARGETING; ENZYME ACTIVATION; INFLAMMATION; INJECTION; KNOCKOUT MOUSE; LIPID BLOOD LEVEL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR UPREGULATION;

ANILINE COMPOUNDS; ANIMALS; ATHEROSCLEROSIS; CELL ADHESION MOLECULES; CORTICOTROPIN-RELEASING HORMONE; GENE EXPRESSION REGULATION; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; NF-KAPPA B P50 SUBUNIT; PEPTIDE FRAGMENTS; PYRIMIDINES; RECEPTORS, LDL; TRANSCRIPTION FACTORS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 62649100205     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.05.059     Document Type: Article

References (34)

1. Libby P. Inflammation in atherosclerosis. Nature 420 (2002) 868-874
2. Glass C.K., and Witztum J.L. Atherosclerosis: the road ahead. Cell 104 (2001) 503-516
3. Chrousos G.P. The hypothalamic-pituitary-adrenal axis and immune-mediated inflammation. New Engl J Med 332 (1995) 1351-1362
4. Karalis K., Sano H., Redwine J., Listwak S., Wilder R.L., and Chrousos G.P. Autocrine or paracrine inflammatory actions of corticotropin-releasing hormone in vivo. Science 254 (1991) 421-423
5. Katsarou-Katsari A., Singh L.K., and Theoharides T.C. Alopecia areata and affected skin CRH receptor upregulation induced by acute emotional stress. Dermatology 203 (2001) 157-161
6. Springer T.A. Adhesion receptors of the immune system. Nature 346 (1990) 425-434
7. Wilbert-Lampen U., Straube F., Trapp A., Deutschmann A., Plasse A., and Steinbeck G. Effects of corticotropin-releasing hormone (CRH) on monocyte function, mediated by CRH-receptor subtype R1 and R2: a potential link between mood disorders and endothelial dysfunction?. J Cardiovasc Pharmacol 47 (2006) 110-116
8. Agelaki S., Tsatsanis C., Gravanis A., and Margioris A.N. Corticotropin-releasing hormone augments proinflammatory cytokine production from macrophages in vitro and in lipopolysaccharide-induced endotoxin shock in mice. Infect Immun 70 (2002) 6068-6074
9. Kovanen P.T. Mast cell granule-mediated uptake of low density lipoproteins by macrophages: a novel carrier mechanism leading to the formation of foam cells. Ann Med 23 (1991) 551-559
10. Wang Y., Lindstedt K.A., Kovanen P.T., et al. Mast cell granule remnants carry LDL into smooth muscle cells of the synthetic phenotype and induce their conversion into foam cells. Arterioscler Thromb Vasc Biol 15 (1995) 801-810
11. Lee M., Calabresi L., Chiesa G., Franceschini G., and Kovanen P.T. Mast cell chymase degrades apoE and apoA-II in apoA-I-knockout mouse plasma and reduces its ability to promote cellular cholesterol efflux. Arterioscler Thromb Vasc Biol 22 (2002) 1475-1481
12. Leskinen M.J., Kovanen P.T., and Lindstedt K.A. Regulation of smooth muscle cell growth, function and death in vitro by activated mast cells-a potential mechanism for the weakening and rupture of atherosclerotic plaques. Biochem Pharmacol 66 (2003) 1493-1498
13. Duraisamy K.E., Papadopoulou N.G., Michael L.Y., et al. Corticotropin-releasing hormone (CRH) and its structurally related urocortin (UCN) are synthesized and secreted by human mast cells. Endocrinology 145 (2004) 43-48
14. Theoharides T.C., Donelan J.M., Papadopoulou N.I., Jing C., Duraisamy K.E., and Conti P. Mast cells as targets of corticotropinreleasing factor and related peptides. Trends Pharmacol Sci 25 (2004) 563-568
15. Smith E.M., Gregg M., Hashemi F., Schott L., and Hughes T.K. Corticotropin releasing factor (CRF) activation of NF-kappaB-directed transcription in leukocytes. Cell Mol Neurobiol 26 (2006) 1021-1036
16. Tsatsanis C., Androulidaki A., Alissafi T., et al. Corticotropin-releasing factor and the urocortins induce the expression of TLR4 in macrophages via activation of the transcription factors PU.1 and AP-1. J Immunol 176 (2006) 1869-1877
17. Ramirez-Tortosa M.C., Mesa M.D., Aguilera M.C., Quiles J.L., Baro L., and Ramirez-Tortosa C.L. Oral administration of a turmeric extract inhibits LDL oxidation and has hypocholesterolemic effects in rabbits with experimental atherosclerosis. Atherosclerosis 147 (1999) 371-381
18. Lee J.H., Oh G.T., Park S.Y., et al. Cilostazol reduces atherosclerosis by inhibition of superoxide and tumor necrosis factor-alpha formation in low-density lipoprotein receptor-null mice fed high cholesterol. J Pharmacol Exp Ther 313 (2005) 502-509
19. Cybulsky M.I., Iiyama K., Li H.M., Zhu S.N., Chen M., and Iiyama M. A major role for VCAM-1, but not ICAM-1, in early atherosclerosis. J Clin Invest 107 (2001) 1255-1262
20. Collins T., and Cybulsky M.L. NF-kappaB: pivotal mediator or innocent bystander in atherogenesis?. J Clin Invest 107 (2001) 255-264
21. Zbytek B., Pfeffer L.M., and Slominski A.T. Corticotropin-releasing hormone stimulates NF-kappaB in human epidermal keratinocytes. J Endocrinol 181 (2004) R1-R7
22. Sukovich D.A., Kauser K., Shirley F.D., et al. Expression of interleukin-6 atherosclerotic lesions of male ApoE-knockout mice. Arterioscler Thromb 18 (1998) 1498-1505
23. Huber S.A., Sakkinen P., Conze D., Hardin N., and Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb 19 (1999) 2364-2367
24. Venihaki M., Dikkes P., Carrigan A., et al. Corticotropin-releasing hormone regulates IL-6 expression during inflammation. J Clin Invest 108 (2001) 1159-1166
25. Leu S.J., and Singh V.K. Stimulation of interleukin-6 production by corticotropin- releasing factor. Cell Immunol 143 (1992) 220-227
26. Valdez G.R., Sabino V., and Koob G.F. Increased anxiety-like behavior and ethanol self-administration in dependent rats: reversal via corticotropin-releasing factor-2 receptor activation. Alcohol Clin Exp Res 28 (2004) 865-872
27. Brar B.K., Jonassen A.K., Egorina E.M., et al. Urocortin-II and urocortin-III are cardioprotective against ischemia reperfusion injury: an essential endogenous cardioprotective role for corticotropin releasing factor receptor type 2 in the murine heart. Endocrinology 145 (2004) 24-35
28. Gehlert D.R., Shekhar A., Morin S.M., et al. Stress and central urocortin increase anxiety-like behavior in the social interaction test via the CRF1 receptor. Eur J Pharmacol 509 (2005) 145-153
29. Wlk M., Wang C.C., Venihaki M., et al. Corticotropin-releasing hormone antagonists possess anti-inflammatory effects in the mouse ileum. Gastroenterology 123 (2002) 505-515
30. McEvoy A.N., Bresnihan B., FitzGerald O., and Murphy E.P. Corticotropin-releasing hormone signaling in synovial tissue from patients with early inflammatory arthritis is mediated by the type 1 alpha corticotropin-releasing hormone receptor. Arthritis Rheum 44 (2001) 1761-1767
31. Kaneko K., Kawana S., Arai K., and Shibasaki T. Corticotropin-releasing factor receptor type 1 is involved in the stress-induced exacerbation of chronic contact dermatitis in rats. Exp Dermatol 12 (2003) 47-52
32. 1 receptor antagonists for the treatment of depression and anxiety. Exp Clin Psychopharmacol 15 (2007) 519-528
33. Van Gaalen M.M., Stenzel-Poore M.P., Holsboer F., and Steckler T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur J Neurosci 15 (2002) 2007-2015
34. Paterniti S., Zureik M., Ducimetière P., Touboul P.J., Fève J.M., and Alpérovitch A. Sustained anxiety and 4-year progression of carotid atherosclerosis. Arterioscler Thromb Vasc Biol 21 (2001) 136-141